Creative Planning boosted its position in KemPharm Inc. (NASDAQ:KMPH) by 4,571.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 410,794 shares of the specialty pharmaceutical company’s stock after buying an additional 402,000 shares during the period. Creative Planning owned about 2.80% of KemPharm worth $1,844,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of the company. Goldman Sachs Group Inc. increased its stake in KemPharm by 37.2% in the first quarter. Goldman Sachs Group Inc. now owns 85,753 shares of the specialty pharmaceutical company’s stock worth $1,243,000 after buying an additional 23,244 shares during the last quarter. Parkwood LLC bought a new position in shares of KemPharm during the second quarter valued at about $107,000. William Harris Investors Inc. increased its position in shares of KemPharm by 93.3% in the second quarter. William Harris Investors Inc. now owns 30,891 shares of the specialty pharmaceutical company’s stock valued at $123,000 after buying an additional 14,911 shares during the period. Vanguard Group Inc. increased its position in shares of KemPharm by 3.4% in the second quarter. Vanguard Group Inc. now owns 318,210 shares of the specialty pharmaceutical company’s stock valued at $1,267,000 after buying an additional 10,390 shares during the period. Finally, BlackRock Fund Advisors increased its position in shares of KemPharm by 8.6% in the second quarter. BlackRock Fund Advisors now owns 219,172 shares of the specialty pharmaceutical company’s stock valued at $872,000 after buying an additional 17,400 shares during the period. Institutional investors own 45.53% of the company’s stock.
Shares of KemPharm Inc. (NASDAQ:KMPH) traded down 1.28% during trading on Friday, hitting $3.85. 9,445 shares of the stock traded hands. The company has a 50 day moving average price of $3.99 and a 200 day moving average price of $4.68. KemPharm Inc. has a 12 month low of $3.20 and a 12 month high of $20.60. The firm’s market cap is $56.39 million.
Several research analysts have recently issued reports on KMPH shares. Zacks Investment Research downgraded shares of KemPharm from a “buy” rating to a “hold” rating in a report on Wednesday, October 12th. Canaccord Genuity reaffirmed a “buy” rating on shares of KemPharm in a research report on Wednesday, August 10th.
In other KemPharm news, EVP Daniel L. Cohen acquired 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 6th. The shares were acquired at an average price of $4.75 per share, with a total value of $47,500.00. Following the completion of the purchase, the executive vice president now directly owns 1,310 shares of the company’s stock, valued at approximately $6,222.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 22.80% of the company’s stock.
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).